Neutropenia is a clinical condition characterized by an abnormally low concentration of neutrophils in the blood, which are the primary white blood cells responsible for defending the body against bacterial and fungal infections. In clinical practice, neutropenia is typically defined by an absolute neutrophil count (ANC) of fewer than 1,500 cells per microliter of blood. The severity of the condition is classified into three levels: mild (1,000 to 1,500 cells/µL), moderate (500 to 1,000 cells/µL), and severe (less than 500 cells/µL). Patients with severe neutropenia, particularly when the count drops below 200 cells/µL (agranulocytosis), are at an exceptionally high risk of developing life-threatening systemic infections and sepsis. The pathophysiology involves either a decrease in the production of neutrophils in the bone marrow, an increase in their destruction in the peripheral blood or spleen, or an abnormal distribution (sequestration) within the vascular system.
Distinguish between neutropenia and agranulocytosis by documenting the Absolute Neutrophil Count or ANC value to support code selection and severity documentation.
Example: Patient with Stage IV breast cancer presents with a white blood cell count of 1.2 and an Absolute Neutrophil Count of 450, representing severe agranulocytosis secondary to cancer chemotherapy. Management involves withholding current cycle of Paclitaxel and starting daily Filgrastim injections for moderate risk of sepsis.
Billing Focus: Documentation of the ANC under 500 confirms the clinical definition of agranulocytosis for D70.1.
Explicitly link the neutropenia to the causative agent when it is drug-induced, identifying the specific pharmaceutical or antineoplastic medication.
Example: Patient develops profound neutropenia directly caused by Clozapine therapy for refractory schizophrenia. ANC is 800. Medication was discontinued immediately. This drug-induced neutropenia is documented as a primary complication of psychiatric pharmacotherapy.
Billing Focus: Requires linking the condition code D70.2 with the external cause code for the specific drug (T43.3X5A).
Document the presence of fever or infection in conjunction with neutropenia to accurately capture the syndrome of febrile neutropenia, which may require additional coding.
Example: The patient presents with an oral temperature of 101.8 degrees Fahrenheit and an ANC of 300 following chemotherapy. Assessment: Febrile neutropenia secondary to antineoplastic chemotherapy. Admission for broad-spectrum IV antibiotics and monitoring for sepsis.
Billing Focus: Febrile neutropenia requires coding both the neutropenia D70.1 and the fever R50.81.
Specify the clinical phenotype of the neutropenia such as cyclic, congenital, or idiopathic to ensure the most specific ICD-10-CM code assignment.
Example: A 4-year-old male with a history of recurrent oral ulcers and skin infections every 21 days. Documentation confirms Cyclic Neutropenia based on serial CBCs showing predictable ANC nadirs. Genetic testing positive for ELANE mutation.
Billing Focus: Supports D70.4 for cyclic neutropenia rather than the unspecified D70.9.
Clarify if the neutropenia is a manifestation of an underlying bone marrow disorder such as myelodysplastic syndrome or aplastic anemia.
Example: Bone marrow biopsy reveals myelodysplastic syndrome with multilineage dysplasia. The resulting neutropenia is a manifestation of the MDS. Treatment involves supportive care with growth factors to maintain ANC above 1000.
Billing Focus: If the neutropenia is due to MDS, the MDS code D46.9 takes precedence as the primary etiology.
Identify if the neutropenia is secondary to a systemic infection, particularly viral infections like HIV or hepatitis.
Example: Patient with known HIV-1 infection presents with falling white cell counts. ANC is 1100. Assessment: Neutropenia due to HIV infection. Current antiretroviral therapy maintained; no active opportunistic infections noted at this time.
Billing Focus: Requires code D70.3 for neutropenia due to infection, sequenced after the infection code B20.
Typically used for managing established neutropenia patients requiring lab review and medication adjustment.
Appropriate for stable neutropenia patients requiring routine monitoring and ANC checks.
The primary laboratory test used to calculate the Absolute Neutrophil Count (ANC).
Direct measurement of the total white cell count to assess overall immune status.
Performed to rule out marrow failure, MDS, or malignancy as the cause of neutropenia.
Used for the administration of Filgrastim (G-CSF) to stimulate neutrophil production.
Identifies the cause of neutropenia in many cancer patients (secondary to chemotherapy).
Commonly used for the initial evaluation of a patient referred for an abnormally low WBC count.
Essential for identifying morphological changes like hypersegmentation or toxic granulations.
Used in the evaluation of large granular lymphocyte leukemia (LGL), which often causes neutropenia.